Subcategory
Other indications (e.g. myeloproliferative diseases)
Trial Type
Follow-Up Treatment
Description for experts
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor
Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment
Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Description for laymen
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor
Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment
Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
JSON Data
{
"short_title": "TELIOS TL-895-201",
"data_mode": "910",
"data_mode_number": "000000012",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "rezidiv_haema",
"ctgov_number": null,
"eudract_number": "2020-002393-27",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Eine unverblindete, multizentrische Studie der Phase II zu TL-895 bei Patienten mit rezidivierter/refrakt\u00e4rer Myelofibrose, Januskinase-Inhibitor-intoleranter Myelofibrose und Myelofibrose, f\u00fcr die eine Behandlung mit einem Januskinase-Inhibitor nicht geeignet ist",
"description_laie_en": " A Phase 2 Multicenter Study of TL-895 in Subjects with \r\n A Phase 2 Multicenter Study of TL-895 in Subjects with \r\nA Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor \r\nIntolerant Myelofibrosis, Janus Kinase Inhibitor Treatment \r\nIneligible Myelofibrosis, or Indolent Systemic Mastocytosis",
"description_expert_de": "Eine unverblindete, multizentrische Studie der Phase II zu TL-895 bei Patienten mit rezidivierter/refrakt\u00e4rer Myelofibrose, Januskinase-Inhibitor-intoleranter Myelofibrose und Myelofibrose, f\u00fcr die eine Behandlung mit einem Januskinase-Inhibitor nicht geeignet ist",
"description_expert_en": " A Phase 2 Multicenter Study of TL-895 in Subjects with \r\n A Phase 2 Multicenter Study of TL-895 in Subjects with \r\nA Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor \r\nIntolerant Myelofibrosis, Janus Kinase Inhibitor Treatment \r\nIneligible Myelofibrosis, or Indolent Systemic Mastocytosis",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 22
}
